These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9194354)

  • 21. Standardizing economic appraisal of health technology in the European Community.
    Rovira J
    Soc Sci Med; 1994 Jun; 38(12):1675-8. PubMed ID: 8047926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Institute for Quality and Efficiency in Health Care: Germany.
    Nasser M; Sawicki P
    Issue Brief (Commonw Fund); 2009 Jul; 57():1-12. PubMed ID: 19639711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marketplace. Assessing medical innovations: how health plans pick what technology to cover.
    Moskowitz DB
    Faulkner Grays Med Health; 1997 May; 51(21):suppl 2 p.. PubMed ID: 10167124
    [No Abstract]   [Full Text] [Related]  

  • 25. Health technology assessment in Australia: challenges ahead.
    Jackson TJ
    Med J Aust; 2007 Sep; 187(5):262-4. PubMed ID: 17767428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The price of progress. Getting insurers to cover new procedures is often difficult.
    Borges W
    Tex Med; 2001 Jun; 97(6):56-9. PubMed ID: 11430199
    [No Abstract]   [Full Text] [Related]  

  • 27. The limited regulatory potential of medical technology assessment.
    Elhauge E
    Va Law Rev; 1996 Nov; 82(8):1525-1622. PubMed ID: 16715565
    [No Abstract]   [Full Text] [Related]  

  • 28. Relative effectiveness and the European pharmaceutical market.
    Jönsson B
    Eur J Health Econ; 2011 Apr; 12(2):97-102. PubMed ID: 21267624
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of technology assessment in health benefits coverage for medical devices.
    Braslow NM; Shatin D; McCarthy DB; Newcomer LN
    Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From principle to public policy: using cost-effectiveness analysis.
    Neumann PJ; Johannesson M
    Health Aff (Millwood); 1994; 13(3):206-14. PubMed ID: 7927151
    [No Abstract]   [Full Text] [Related]  

  • 31. Eunethta: further steps towards European cooperation on health technology assessment.
    Guegan EW; Huić M; Teljeur C
    Int J Technol Assess Health Care; 2014 Nov; 30(5):475-7. PubMed ID: 25747555
    [No Abstract]   [Full Text] [Related]  

  • 32. The trouble with medical innovation.
    Moskowitz DB
    Bus Health; 1999 May; 17(5):38-42. PubMed ID: 10387675
    [No Abstract]   [Full Text] [Related]  

  • 33. Market uptake of orphan drugs--a European analysis.
    Picavet E; Annemans L; Cleemput I; Cassiman D; Simoens S
    J Clin Pharm Ther; 2012 Dec; 37(6):664-7. PubMed ID: 22731105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Best practice in undertaking and reporting health technology assessments. Working group 4 report.
    Velasco M; Perleth M; Drummond M; Gürtner F; Jørgensen T; Jovell A; Malone J; Rüther A; Wild C
    Int J Technol Assess Health Care; 2002; 18(2):361-422. PubMed ID: 12053427
    [No Abstract]   [Full Text] [Related]  

  • 35. Coverage and reimbursement for heart transplantation.
    Evans RW
    Int J Technol Assess Health Care; 1986; 2(3):425-49. PubMed ID: 10301275
    [No Abstract]   [Full Text] [Related]  

  • 36. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
    Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
    Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Education and support networks for assessment of health interventions. Working group 5 report.
    Antes G; Briones E; Britton M; Burnand B; Engel G; Gallo P; Pinto CG; Siebzehner MI; Jönsson B; Landa K; Liaropoulos L; Liberati A; Mäkelä M; Jensen BN; Piestiniene A; Raspe H; Synnott A
    Int J Technol Assess Health Care; 2002; 18(2):423-46. PubMed ID: 12053428
    [No Abstract]   [Full Text] [Related]  

  • 38. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia.
    Fischer KE; Heisser T; Stargardt T
    Health Policy; 2016 Oct; 120(10):1115-1122. PubMed ID: 27628196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of subjective values to medical technology assessment and health policy.
    Diamond GA
    J Invasive Cardiol; 1993; 5(1):17-22. PubMed ID: 10148297
    [No Abstract]   [Full Text] [Related]  

  • 40. Health Technology Assessment as a Priority-Setting Tool for Universal Health Coverage: The Call for Global Action at the Prince Mahidol Award Conference 2016.
    Teerawattananon Y; Luz A
    Pharmacoeconomics; 2016 Jan; 34(1):1-3. PubMed ID: 26660528
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.